Viral hemorrhagic fevers are a group of febrile illnesses that constitutes a challenge to public health. Viral hemorrhagic fevers are endemic in some areas of the world and are often associated with high morbidity and mortality. Due to high mortality rates and outbreaks that are irregular and hard to predict, difficulties arise when undertaking clinical studies to assess new treatments against viral hemorrhagic fevers. To provide an extensive overview of viral hemorrhagic fevers, we conducted a systematic review to retrieve available information on number of cases, mortality and treatments of viral hemorrhagic fevers. We found that cases number and mortality varied greatly across outbreaks and across countries within each viral hemorrhagic fever. The number of studies on viral hemorrhagic fever treatments was very limited with very few methodologically strong studies. Moreover, for several viral hemorrhagic fevers we did not identify specific investigational therapeutic option with strong proof of effectiveness on mortality. Therefore, there is a high need to conduct methodologically strong studies to investigate treatments against viral hemorrhagic fevers.
BackgroundViral hemorrhagic fevers (VHFs) are a group of diseases, which can be endemo-epidemic in some areas of the world. Most of them are characterized by outbreaks, which occur irregularly and are hard to predict. Innovative medical countermeasures are to be evaluated but due to the field specificities of emerging VHF, challenges arise when implementing clinical studies. To assess the state of the art around VHFs, we conducted a systematic review for all reports and clinical studies that included specific results on number of cases, mortality and treatment of VHFs.MethodsThe search was conducted in January 2020 based on PRISMA guidelines (PROSPERO CRD42020167306). We searched reports on the WHO and CDC websites, and publications in three international databases (MEDLINE, Embase and CENTRAL). Following the study selection process, qualitative and quantitative data were extracted from each included study. A narrative synthesis approach by each VHF was used. Descriptive statistics were conducted including world maps of cases number and case fatality rates (CFR); summary tables by VHF, country, time period and treatment studies.ResultsWe identified 141 WHO/CDC reports and 126 articles meeting the inclusion criteria. Most of the studies were published after 2010 (n = 97 for WHO/CDC reports and n = 93 for publications) and reported number of cases and/or CFRs (n = 141 WHO/CDC reports and n = 88 publications). Results varied greatly depending on the outbreak or cluster and across countries within each VHF. A total of 90 studies focused on Ebola virus disease (EVD). EVD outbreaks were reported in Africa, where Sierra Leone (14,124 cases; CFR = 28%) and Liberia (10,678 cases; CFR = 45%) reported the highest cases numbers, mainly due to the 2014–2016 western Africa outbreak. Crimean-Congo hemorrhagic fever (CCHF) outbreaks were reported from 31 studies in Africa, Asia and Europe, where Turkey reported the highest cases number (6,538 cases; CFR = 5%) and Afghanistan the last outbreak in 2016/18 (293 cases; CFR = 43%).Regarding the 38 studies reporting results on treatments, most of them were non-randomized studies (mainly retrospective or non-randomized comparative studies), and only 10 studies were randomized controlled trials. For several VHFs, no specific investigational therapeutic option with strong proof of effectiveness on mortality was identified.ConclusionWe observed that number of cases and CFR varied greatly across VHFs as well as across countries within each VHF. The number of studies on VHF treatments was very limited with very few randomized trials and no strong proof of effectiveness of treatment against most of the VHFs. Therefore, there is a high need of methodologically strong clinical trials conducted in the context of VHF.
IntroductionViral hemorrhagic fevers (VHFs) are a group of febrile illnesses caused by four families of RNA viruses: arenaviridae, filoviridae, bunyaviridae and flaviviridae. [1] These highly infectious viruses are mainly zoonotic; meaning they naturally exist in animal or insect populations. [2] When a person encounter an infected animal or insect, the virus can spread through spillover into the human population, and subsequently is transmitted from person-to-person through contact with blood or other body fluids. Whatever their capacity to drive paramount hemorrhagic manifestations, many VHFs can cause severe, life-threatening disease. The agents that are causative of VHF are often classified as Biosafety Level 4 (BSL-4) pathogens that require special laboratory facilities with the highest level of safety measures. [2,3] VHFs are distributed worldwide and are often associated with high morbidity and mortality. Most of them are characterized by clusters or even outbreaks occurring irregularly and almost resulting from spillover or more recently from human reservoirs constituted by immunologically preserved sanctuaries where the virus may persist after recovery of conversant survivors.Patient outcomes are highly associated with the timing of curative treatment with improved outcomes when the specific or supportive therapy is started early. [4,5] Hence, VHF care remains essentially supportive and some VHFs are treated only with basic medical care that is not always reaching the optimized level of standards aimed to prevent or control the multi-systemic disorders that account for bad outcome. [2,5,6] Available VHF drugs are limited and clinical data on the efficacy of VHFs drugs is restricted. [4,5] New investigational treatments need to be evaluated but due to the field specificities of emerging VHF, difficulties arise when conducting clinical studies. Indeed, hard to predict outbreak duration leads to limited number of recruited patients. Moreover high case fatality rate (CFR) leads to reluctance to use methodologically strong trial design such as randomized controlled trials as part of the patients will not receive the potentially beneficial treatment. [7]VHFs have recently caused various outbreaks around the world. To assess the state of the art around VHFs, we systematically reviewed the World Health Organization (WHO) and Centers for Disease Control (CDC) websites and published literature for all reports and clinical studies that included specific results on number of cases, mortality and treatments of VHFs. We decided to focus mostly on VHFs caused by a selection of arenaviridae, filoviridae, bunyaviridae and flaviviridae and did not look at some other important VHF conditions such as the severe dengue and yellow fever.MethodsThe systematic review was registered on the International prospective register of systematic reviews (PROSPERO 2020 CRD 42020167306). The objective of the systematic review was to review the case fatality rates, number of cases and treatment options of VHFs. The initial protocol also included the review of sequelaes, which will not be presented here.Eligibility criteriaThe PICOS (Participants, Intervention, Comparison, Outcomes and Study types) framework was used to identify relevant data.ParticipantsHumans infected with a pathogen causative of a VHF from the following list: [8]Alkhurma hemorrhagic fever (AHF)Argentine hemorrhagic fever (ArHF)Bolivian hemorrhagic fever (BHF)Chapare hemorrhagic fever (CHF)Crimean-Congo hemorrhagic fever (CCHF)Ebola virus disease (EVD)Hantavirus pulmonary syndrome (HPS)Hemorrhagic fever with renal syndrome (HFRS)Kyasanur Forest disease (KFD)Lassa fever (LF)Lujo hemorrhagic fever (LHF)Lymphocytic choriomeningitis (LCM)Marburg virus disease (MVD)Omsk hemorrhagic fever (OHF)Rift Valley fever (RVF)Sabia-associated hemorrhagic fever (SHF)Tick-borne encephalitis (from a hemorrhagic variant)Venezuelan hemorrhagic fever (VeHF)Interventions/ComparisonsThis review did not focus on any specific intervention.OutcomesAny studies reporting number of cases and/or CFR and/or mortality rates associated with treatments of a VHF were included.Study typesOfficial information from WHO/CDC and national health websites, cross-sectional, cohort/case-control studies, descriptive reports and clinical trials were included.Study languageIncluded studies were limited to studies published in English or French. The following types of study were deemed ineligible; case reports, case series, systematic reviews and meta-analyses.Search strategyThe systematic review consisted in two parts. The first search was conducted in December 2019 on the WHO and CDC websites to identify the number of cases and deaths associated with each disease by year and by country. The second search consisted in a systematic literature search of bibliographic databases based on the PRISMA guideline. Relevant studies were identified by searching MEDLINE, Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library. We searched the electronic databases until January 21st, 2020. Search terms were developed using a combination of MeSH/EMTREE terms and free-text terms to capture the relevant populations, outcomes and study types (cf. S1 Fig in Supplementary Material). Reference lists of included studies were not reviewed. Additional hand searches were performed on national health websites.Study selectionFor the systematic literature search, after removing duplicates, two researchers (DB and GM) independently evaluated all identified citations based on titles and/or abstracts. In case of disagreement, a third researcher (CL) served as tiebreaker. Full-text publications of studies included based on title and abstract were retrieved and reviewed by two researchers (DB and ME) to assess eligibility based on the inclusion/exclusion criteria. A third researcher (CL) served as a tiebreaker for any discordant decisions. Justification for study exclusion was documented.Data extractionInformation identified from the WHO and CDC websites were extracted for each disease by period and by country. For the systematic literature search, following the study selection process, qualitative and quantitative data were extracted from each of the included articles. Numbers were extracted as reported in each study. If the CFR was not reported in a study, the number of cases and the number of deaths were used, if available, to estimate the missing CFR.Risk of bias assessmentQuality assessment was performed using the Newcastle-Ottawa Quality Assessment Form [9] to evaluate cohort studies, and the Risk of Bias (RoB) tool described in the Cochrane Handbook for Systematic Reviews of Interventions [10] to evaluate randomized clinical trials.Strategy for data synthesisA narrative synthesis approach by disease was used for each outcome. Descriptive statistics were conducted to describe the published articles and WHO/CDC reports. World map of the total number of cases and CFR were produced and summary tables of the number of cases and CFR by VHF, country and time period were also produced. Summary tables reporting the characteristics and results of each study on VHF treatments were produced.World maps were produced using R software version 3.6.0.ResultsA total of 57 reports were identified from the WHO website, and 96 reports from the CDC website. After removing duplicates, 141 reports were extracted. After removing duplicates, 4 461 publications were identified from Medline, Embase, CENTRAL and through hand searches. We excluded 4 153 publications based on the screening of titles and abstracts. A total of 308 publications were included for full text review. Finally, 126 publications met the inclusion criteria and were extracted. The selection process and the numbers at each stage are shown in Fig 1. The exhaustive lists of included publications and WHO and CDC reports are reported in S1 and S2 Tables in Supplementary Material.10.1371/journal.pntd.0010889.g001Fig 1Study selection flow diagram: A. For the WHO and CDC websites search; B. For the systematic literature search.Characteristics of included studiesThe characteristics of the included studies are summarized in Table 1. Most of the studies were published after 2010 (69%, n = 97 for WHO and CDC reports and 74%, n = 93 for publications) and were conducted mainly in Africa (57%, n = 81 for WHO and CDC reports and 48%, n = 60 for publications). The majority of studies reporting number of cases and/or CFR were descriptive reports (100%, n = 141 for WHO and CDC reports and 90%, n = 79 for publications) followed by retrospective studies (10%, n = 9 for publications). Regarding studies reporting results on treatments, 32% (n = 12) of them were retrospective studies, followed by 26% (n = 10) of randomized controlled trial and 16% (n = 6) of non-randomized comparative studies. Most of WHO and CDC reports focused on EVD (33%, n = 47), followed by HPS (18%, n = 26), LF (17%, n = 24) and RVF (16%, n = 23). In terms of publications, most of them focused also on EVD (33%, n = 43), followed by CCHF (21%, n = 27), HFRS (14%, n = 18) and HPS (10%, n = 13). No relevant data were identified for KFD, LCM and tick-borne encephalitis (from a hemorrhagic variant).10.1371/journal.pntd.0010889.t001Table 1Characteristics of included studies. WHO/CDC reports (N = 141)Publications (N = 126)
Year of publication
Before 200023 (16%)13 (10%)Between 2000 and 201021 (15%)20 (16%)After 201097 (69%)93 (74%)
Region of interest Africa81 (57%)60 (48%)America33 (23%)18 (14%)Asia11 (8%)40 (32%)Asia and Europe-1 (1%)Europe16 (11%)6 (5%)Worldwide-1 (1%)
Study type Studies reporting number of cases and/or CFR N = 141 N = 88 Descriptive report141 (100%)79 (90%) Retrospective study-9 (10%)
Studies reporting results on treatments N = 38 Case-Control Study-2 (5%) Descriptive report-3 (8%) Non-randomized comparative study-6 (16%) Prospective and retrospective study-1 (3%) Randomized Controlled trial-10 (26%) Retrospective study-12 (32%) Single-arm trial-4 (10%)
Disease of interest (alphabetical order) Alkhurma hemorrhagic fever (AHF)1 (1%)2 (2%)Argentine hemorrhagic fever (ArHF)0 (0%)3 (2%)Bolivian hemorrhagic fever (BHF)0 (0%)1 (1%)Chapare hemorrhagic fever (CHF)2 (1%)0 (0%)Crimean-Congo hemorrhagic fever (CCHF)4 (3%)27 (21%)Ebola Virus Disease (EVD)47 (33%)43 (33%)Hantavirus Pulmonary Syndrome (HPS)26 (18%)13 (10%)Hemorrhagic fever with renal syndrome (HFRS)0 (0%)18 (14%)Kyasanur Forest Disease (KFD)0 (0%)0 (0%)Lassa fever (LF)24 (17%)7 (5%)Lujo hemorrhagic fever (LHF)1 (1%)1 (1%)Lymphocytic choriomeningitis (LCM)0 (0%)0 (0%)Marburg virus disease (MVD)13 (9%)1 (1%)Omsk hemorrhagic fever (OHF)0 (0%)1 (1%)Rift Valley fever (RVF)23 (16%)9 (7%)Sabia-associated hemorrhagic fever/Sabia hemorrhagic fever (SHF)0 (0%)1 (1%)Tick-borne Encephalitis (from a hemorrhagic variant) (TBE)0 (0%)0 (0%)Venezuelan hemorrhagic fever (VeHF)0 (0%)2 (2%)Risk of bias of included studiesOn the 38 studies reporting results on treatments, 10 were randomized trials and 28 were non-randomized. Regarding the randomized comparative studies, only two were classified as having a “low risk of bias”, both published after 2010, and the other eight studies were classified as having “some concerns” (cf. S3 Table). Regarding the non-randomized studies, 13 were classified as “poor quality”, 5 as “fair quality” and 10 as “good quality” (cf. S4 Table). On those 28 non-randomized studies, 6 were published before 2010 and 67% of them (n = 4/6) were classified as “poor quality”, compared with 41% (n = 9/22) for those published after 2010.The 88 studies reporting number of cases and CFR were evaluated using the Newcastle-Ottawa Quality Assessment Form: 59 were classified as “poor quality” and 29 as “fair quality” (cf. S5 Table). On these 88 studies, 31 were published before 2010 and a similar proportion than those published after 2010 were classified as “poor quality” (65%, n = 20/31, for studies before 2010, compared with 68%, n = 45/66, for studies published after 2010).Number of cases and CFRThe worldwide distribution of VHFs by country is reported in Fig 2. We identified studies reporting outbreaks of at least one VHF across 55 countries. We found studies on 4 different VHFs in South Africa: CCHF, RVF, MVD and LHF. Based on identified studies, a total of 16 countries were associated with 2 VHFs, mainly in Africa with 9 countries, followed by America with 3 countries and Asia and Europe with 2 countries each. More detailed results are reported below for the VHFs with at least 5 studies. They are presented by alphabetical order.10.1371/journal.pntd.0010889.g002Fig 2Worldwide distribution of VHF.The color denotes the number of VHF with at least one outbreak reported by country and the acronyms denote the names of the VHFs. Note: AHF, Alkhurma hemorrhagic fever; ArHF, Argentine hemorrhagic fever; BHF, Bolivian hemorrhagic fever; CHF, Chapare hemorrhagic fever; CCHF, Crimean-Congo hemorrhagic fever; EVD, Ebola Virus Disease; HPS, Hantavirus Pulmonary Syndrome; HFRS, Hemorrhagic fever with renal syndrome; LF, Lassa fever; LHF, Lujo hemorrhagic fever; MVD, Marburg virus disease; OHF, Omsk hemorrhagic fever; RVF, Rift Valley fever; SHF, Sabia hemorrhagic fever; VeHF, Venezuelan hemorrhagic fever. Maps were generated with the ‘maps’ R package using data from the Natural Earth Project (the 1:50m resolution version).Crimean-Congo hemorrhagic fever (CCHF)The distribution of CCHF cases and CRFs are reported in Fig 3. Cases were reported in Africa, Asia and Europe in the following countries: Afghanistan, Bulgaria, Georgia, Iran, Iraq, Kazakhstan, Kosovo, Mauritania, Oman, Pakistan, South Africa, Tajikistan, Turkey and Uzbekistan. The first documented cases were reported in 1948–1969 in Kazakhstan (89 cases, CFR = 25%). At the date of the review, the country with the highest reported number of cases was Turkey with a total of 6,538 cases (CFR = 5%) and the last documented cases reported in 2016–2018 in Afghanistan (293 cases, CFR = 43%). More details by country and period are reported in S6 Table.10.1371/journal.pntd.0010889.g003Fig 3Distribution of number of cases and CFR of Crimean-Congo hemorrhagic fever.The size of the bubble is proportional with the number of cases reported and the color denotes the level of CFR by country. Note: Maps were generated with the ‘maps’ R package using data from the Natural Earth Project (the 1:50m resolution version).Ebola virus disease (EVD)The distribution of EVD cases and CRFs are reported in Fig 4. Outbreaks were reported in sub-saharan Africa in the following countries: Democratic Republic of the Congo, Gabon, Republic of Guinea, Liberia, Mali, Nigeria, Sierra Leone, Sudan and Uganda. The first reported outbreak took place in 1976 in the Democratic Republic of the Congo (318 cases, CFR = 88%) and Sudan (284 cases, CFR = 53%). At the date of the review, the countries with the highest reported number of cases were Sierra Leone with a total of 14,124 cases (CFR = 28%) and Liberia with 10,678 cases (CFR = 45%), due to the 2014–2016 western Africa outbreak.10.1371/journal.pntd.0010889.g004Fig 4Distribution of number of cases and CFR of Ebola Virus Disease.The size of the bubble is proportional with the number of cases reported and the color denotes the level of CFR by country. Note: Maps were generated with the ‘maps’ R package using data from the Natural Earth Project (the 1:50m resolution version).The reported CFRs since 2010 varied greatly across countries (cf. S7 Table). In total, 28% in Sierra Leone in 2014–2016 (14,124 cases), 40% in Nigeria in 2014 (20 cases), 41% in Uganda in 2012 (17 cases), 45% in Liberia (10,678 cases), 66% in the Democratic Republic of the Congo in 2018 (3,470 cases), 67% in Guinea in 2014–2016 (3,811 cases) and 75% in Mali in 2014 (8 cases).Hantavirus pulmonary syndrome (HPS)The distribution of HPS cases and CRFs are reported in Fig 5. Cases were reported in America in the following countries: Argentina, Brazil, Chile, Panama, Paraguay and USA. The first documented cases were reported in 1993 in the USA (48 cases, CFR = 56%) and Brazil (884 cases from 1993 to 2006, CFR = 39%). At the date of the review, the countries with the highest documented number of cases were Brazil with 2,370 cases (CFR = 39%) and the last documented cases were reported in 2018 in USA (3 cases, CFR = 67%). More details by country and period are reported in S8 Table.10.1371/journal.pntd.0010889.g005Fig 5Distribution of number of cases and CFR of Hantavirus Pulmonary Syndrome.The size of the bubble is proportional with the number of cases reported and the color denotes the level of CFR by country. Note: Maps were generated with the ‘maps’ R package using data from the Natural Earth Project (the 1:50m resolution version).Hemorrhagic fever with renal syndrome (HFRS)HFRS cases were reported in Asia and Europe in the following countries: China, Croatia, Finland, Belgium, France, Germany, Netherlands, Luxembourg, South Korea, Montenegro and Russia. The first documented cases were reported in 1931–1941 in China (10,000 cases, CFR = 30%). At the date of the review, the country with the highest reported number of cases was China with 1,306,812 cases (CFR = 3%) and the last documented cases reported in 2000–2017 in Russia (131,590 cases, CFR = 0.4%). More details by country and period are reported in S9 Table.Lassa fever (LF)The distribution of LF cases and CRFs are reported in Fig 6. Cases were reported in western Africa in the following countries: Benin, Liberia, Nigeria, Sierra Leone and Guinea. We identified a study which reported the first outbreak in 1996–1999 in Guinea (22 cases, CFR = 18%). At the date of the review, the country with the highest reported number of cases was Nigeria with 2,287 cases (CFR = 23%) and the last documented cases reported in 2019 in South-West Nigeria (554 cases, CFR = 22%). More details by country and period are reported in S10 Table.10.1371/journal.pntd.0010889.g006Fig 6Distribution of number of cases and CFR of Lassa fever.The size of the bubble is proportional with the number of cases reported and the color denotes the level of CFR by country. Note: Maps were generated with the ‘maps’ R package using data from the Natural Earth Project (the 1:50m resolution version).Marburg virus disease (MVD)MVD cases were reported in Africa and Europe in the following countries: Angola, Democratic Republic of the Congo, Germany, ex-Yugoslavia, South Africa, Kenya and Uganda. The first documented cases were reported in 1967 in Germany (29 cases, CFR = 24%) and ex-Yugoslavia (2 cases, CFR = 0%) and relied to lab.-accidental transmission in settings that were used to import monkeys from Central Africa. At the date of the review, the country with the highest reported number of cases was Angola with 374 cases (CFR = 88%) and the last documented cases reported in 2017 in Uganda (2 cases, CFR = 100%). More details by country and period are reported in S11 Table.Rift Valley fever (RVF)The distribution of RVF cases and CRFs are reported in Fig 7. Cases were reported in Africa and Asia in the following countries: Egypt, Kenya, Madagascar, Mauritania, Mayotte (France), Mozambique, Niger, Saudi Arabia, Somalia, South Africa, Sudan, Tanzania and Yemen. The first documented cases were reported in 1977–1978 in Egypt (18,000 cases, CFR = 3%). At the date of the review, the country with the highest documented number of cases was Egypt with 18,148 cases (CFR = 3%) and the last documented cases reported in 2018–2019 in Mayotte (129 cases, CFR not reported). More details by country and period are reported in S12 Table.10.1371/journal.pntd.0010889.g007Fig 7Distribution of number of cases and CFR of Rift Valley Fever.The size of the bubble is proportional with the number of cases reported and the color denotes the level of CFR by country. Note: Maps were generated with the ‘maps’ R package using data from the Natural Earth Project (the 1:50m resolution version).Other VHFsThe remaining VHFs reported cases in one country each: Saudi Arabia for AHF (335 cases, CFR = 2%), Argentina for ArHF (981 cases, CFR not reported), Bolivia for BHF (690 cases, CFR = 23%), South Africa for LHF (5 cases, CFR = 80%), Russia for OHF (1144 cases, CFR = 14%), Brazil for SHF (4 cases, CFR = 2%) and Venezuela for VeHF (728 cases, CFR = 23%). More details by VHF and period are reported in S13 Table.VHFs treatmentsPublications evaluating the efficacy of specific treatments on mortality were identified for Argentine hemorrhagic fever, Crimean-Congo hemorrhagic fever, Ebola Virus Disease, Hantavirus Pulmonary Syndrome, Hemorrhagic fever with renal syndrome and Lassa fever (cf. Tables 2 and 3). More details on each investigational treatment are reported in S14 Table. Detailed results are reported below for the VHFs with at least one study. They are presented by alphabetical order.10.1371/journal.pntd.0010889.t002Table 2Characteristics of included studies reporting results on treatments by VHF.StudyStudy designRandomisationBlindingCountryTreatmentComparator
Argentine hemorrhagic fever
Maiztegui 1979 [11]Randomized Controlled trialYesDouble-blindArgentinaImmune plasmaNormal plasma obtained from donors without a history of AHF who were residents of Buenos Aires, a city located outside the endemic area of the disease.
Crimean-Congo hemorrhagic fever
Elaldi 2009 [12]Non-randomized comparative studyNoNATurkeyRibavirin + Supportive therapySupportive therapy (patients who were diagnosed in 2003)Dokuzoguz 2013 [13]Prospective and retrospective studyNoNATurkeyRibavirin +/- CorticosteroidNo ribavirin +/- corticosteroidCevik 2008 [14]Descriptive reportNoNATurkeyRibavirin + Supportive therapySupportive therapyYilmaz 2016 [15]Retrospective studyNoNATurkey and IranRibavirin + Supportive therapySupportive therapyIzadi 2009 [16]Case-Control StudyNoNAIranRibavirin + Supportive therapyNRTulek 2012 [17]Case-Control StudyNoNATurkeyRibavirin + Supportive therapySupportive therapy (patients with CCHF of the other infectious diseases department in the same hospital)Koksal 2010 [18]Randomized Controlled trialYesNRTurkeyRibavirin + Supportive therapySupportive therapyMardani 2003 [19]Non-randomized comparative studyNoNAIranRibavirinNo ribavirin (historical controls)Salehi 2013 [20]Randomized Controlled trialYesSingle-blindIranImmune globulins (IGIV) + ribavirin + Supportive therapyRibavirin + Supportive therapy
Ebola Virus Disease
Aluisio 2019 [21]Retrospective studyNoNALiberia and Sierra LeoneIntravenous fluid (IVF) + Supportive therapyNRAluisio 2019 [22]; Aluisio 2019 [23]Retrospective studyNoNALiberia and Sierra LeoneVitamin A supplementation + Supportive therapySupportive therapyAluisio 2020 [24]Retrospective studyNoNALiberia and Sierra LeoneCephalosporin + Supportive therapySupportive therapyBai 2016 [25]Retrospective studyNoNASierra LeoneFavipiravir + Supportive therapySupportive therapySissoko 2016 [26]Single-arm trialNoNAGuineaFavipiravir + Supportive therapyHistorical data (540 patients hospitalized between 15 September and 15 December 2014, the 3 months preceding the start of the JIKI study)Yam 2020 [27]Retrospective studyNoNASierra Leone and LiberiaMultivitamin supplementation + Supportive therapySupportive therapyDunning 2016 [28]Single-arm trialNoNALiberiaBrincidofovir + Supportive therapyNRGignoux 2015 [29]Retrospective studyNoNALiberia• Artemether-Lumefantrine + Supportive therapySupportive therapy• Artesunate-Amodiaquine + Supportive therapyGarbern 2019 [30]Retrospective studyNoNALiberia and Sierra LeoneArtesunate-amodiaquine (ASAQ) + Supportive therapySupportive therapyDunning 2016 [31]Single-arm trialNoNASierra LeoneTKM-130803 + Supportive therapyNRSahr 2017 [32]Non-randomized comparative studyNoNASierra LeoneConvalescent whole blood (CWB) + Supportive therapySupportive therapyKonde 2017 [33]Single-arm trialNANAGuineaIFN-beta 1a + Supportive therapySupportive therapy (Historical cohort). The historical control patients were admitted to the Coyah ETU during the same time period as the IFN beta-1a patients with RT-PCR confirmed blood EBOV. Also included 17 patients who matched the IFN treated patients for eligibility criteria based on <6 days from symptom onset, age, under care in a Guinean treatment centre, who were better matched for baseline CT values.Sadek 1999 [34]Descriptive reportNANADemocratic Republic of the CongoWhole blood transfusion from convalescent patients + Supportive therapyNAVan Griensven 2016 [35]Non-randomized comparative studyNoNAGuineaTransfusion of convalescent plasma + Supportive therapySupportive therapy: Patients who had been admitted to the ETU during the preparatory period of the study while the system for apheresis and pathogen reduction was being set up and those for whom ABO compatible convalescent plasma was not available during the study. At the start of recruitment, there was a sufficient amount of convalescent plasma available to treat all the patients, so a protocol amendment was approved for the control group to consist of patients who were treated at the same ETU before the initiation of the trial.Davey 2016 [36]Randomized Controlled trialYesNoLiberia, Sierra Leone, Guinea and USAZMapp + Supportive therapySupportive therapyMulangu 2019 [37]Randomized Controlled trialYesNADemocratic Republic of the Congo•Remdesivir + Supportive therapyZMapp (intravenous 50mg per kilogram of body weight every third day beginning on day 1 for a total of 3 doses) + Supportive therapy•Mab114 + Supportive therapy•REGN-EB3 + Supportive therapyKerber 2019 [38]Retrospective studyNANAGuineaFavipiravir + Supportive therapySupportive therapy
Hantavirus Pulmonary Syndrome
Chapman 1999 [39]Non-randomized comparative studyNoOpen-labelUnited StatesRibavirinNo ribavirin (contemporaneous patients)Mertz 2004 [40]Randomized Controlled trialYesDouble-blindUSA and CanadaRibavirinPlaceboVial 2013 [41]Randomized Controlled trialYesDouble-blindChileMethylprednisolonePlaceboWernly 2011 [42]Retrospective studyNANAUSAExtracorporeal membrane oxygenation (ECMO) supportPatients intubated when they became hypoxic and placed on ECMO when they became hemodynamically unstableVial 2015 [43]Non-randomized comparative studyNoNAChileImmune plasma infusionNo immune plasma infusion
Hemorrhagic fever with renal syndrome
Gui 1987 [44]Randomized Controlled trialYesSingle-blindChinaRecombinant interferon α-2 + Supportive therapyPlacebo + Supportive therapyDu 2013 [45]Retrospective studyNoNAChinaRenal Replacement Therapy (RRT)No RRTHuggins 1991 [46]Randomized Controlled trialYesDouble-blindChinaRibavirinPlacebo
Lassa fever
Ilori 2019 [47]Descriptive reportNoNANigeriaRibavirin + Supportive therapySupportive therapyMcCormick 1986 [48]Randomized Controlled trialYesNoSierra LeonePHASE 1: No therapy VS Oral Ribavirin VS Lassa convalescent plasmaNo therapyPHASE 2: intravenous ribavirin +/- lassa plasmaNA, Not applicable; NR, Not reported10.1371/journal.pntd.0010889.t003Table 3Mortality results associated with VHFs treatments reported in the included studies.StudyComparisonTreatment group–No.Comparator group–No.TimeTreatment group—Mortality rate (%)Comparator group—Mortality rate (%)p-valueOutcome measureOutcome resultP-value
Argentine hemorrhagic fever
Maiztegui 1979 [11]Immune plasma VS normal plasma9197NR1.116.5<0,01NRNRNR
Crimean-Congo hemorrhagic fever
Elaldi 2009 [12]Ribavirin VS no ribavirin12692First 8 days7.111.90.283Hazard ratio10.33 (1.65–64.71)NRAfter 8 days (to 30 days)---Hazard ratio0.1 (0.01–8.80)NRDokuzoguz 2013 [13]Ribavirin +/- corticosteroids VS no treatmentRibavirin +/- corticosteroids: 23546NR7.710.9NRAdjusted odds ratio0.04 (0.004–0.48)0.01Corticosteroids + Ribavirin VS no treatmentCorticosteroids + Ribavirin: 44217NR20.54.1NRAdjusted odds ratio0.22 (0.039–1.27)0.092Cevik 2008 [14]Ribavirin VS no ribavirin916NR55.543.70.571NRNRNRYilmaz 2016 [15]Ribavirin VS no ribavirin198345NR7.68.40.733NRNRNRIzadi 2009 [16]Patients receiving ribavirin after onset of bleeding VS before onset of bleeding or had no bleeding at all3924NR35.98.3NROdds ratio6.2 (1.3–30.3)0.018Patients receiving ribavirin after the 4th day of disease onset VS within the first 4 days of disease onset2538NR40.015.8NROdds ratio3.6 (1.1–11.6)0.031Tulek 2012 [17]Ribavirin VS no ribavirin91152NR1.15.30.096NRNRNRKoksal 2010 [18]Ribavirin VS supportive therapy6472NR6.35.60.86NRNRNRMardani 2003 [19]Ribavirin VS historical control6912NR11.658.3NRRelative risk in confirmed patients0.20 (0.09–0.45)<0.001Salehi 2013 [20]Immune globulins + ribavirin VS ribavirin1228Until one week after hospitalisation25110.24NRNRNR
Ebola Virus Disease
Aluisio 2019 [21]Intravenous fluid (IVF)7035428 days58.755.10.583NRNRNRAluisio 2019 [22]; Aluisio 2019 [23]Vitamin A supplementation VS no vitamin A supplementation33094During Ebola Treatment Unit care5571.9NRRelative risk reduction of mortality with vitamin A treatment within 48 h0.77 (0.59–0.99)0.041Aluisio 2020 [24]Cephalosporin VS no treatment3606448h58.755.10.583NRNRNRBai 2016 [25]Favipiravir VS supportive care398560 days43.664.70.027NRNRNRSissoko 2016 [26]Favipiravir VS historical control111NAOn-trial54.0555NRNRNRNRYam 2020 [27]Multivitamin supplementation VS no multivitamin supplementation26116348h53.663.8NRNRNRNRDunning 2016 [28]Brincidofovir4NA14 days100NANRNRNRNRGignoux 2015 [29]No Antimalarial Drug Prescription VS Artemether-Lumefantrine19463NR64.465.1NRUnadjusted risk ratio1.01 (0.82–1.25)0.92Artesunate-Amodiaquine VS Artemether-Lumefantrine71194NR50.764.4NRUnadjusted risk ratio0.79 (0.61–1.01)0.06Garbern 2019 [30]Artesunate-amodiaquine VS no treatment22402NR45.572.7NRRisk of death in the matched cohort0.63 (0.37–1.07)0.086Dunning 2016 [31]TKM-130803141820 (individual-level data from patients with PCR-confirmedEbola infection from the 2014–2015 outbreak)14 days7955NRNRNRNRSahr 2017 [32]Convalescent whole blood VS routine care4425NR27.944NROdds ratio for survival2.3 (0.8–6.5)Konde 2017 [33]IFN-beta 1a VS historical control93821 days33.381NR21-day survival based on Kaplan Meier67% in treated patients VS 19% for the control0.026Sadek 1999 [34]Whole blood transfusion from convalescent patients8NANR12.5NRNRNRNRNRVan Griensven 2016 [35]Convalescent plasma VS no treatment8441816 days3138NRRisk difference-7% (-18 to 4)NRDavey 2016 [36]ZMapp VS standard of care353628 days2237NRAbsolute difference-15% (-37 to 7)NRMulangu 2019 [37]•Remdesivir VS ZMapp17516928 days53.149.7NRDifference between groups3.4% (-7.2 to 14)NR•Mab114 VS ZMapp17416928 days35.149.7NRDifference between groups-14.6% (-27.2 to -1.7)0.007•REGN-EB3 VS ZMapp15516928 days33.549.7NRDifference between groups-17.8% (-28.9 to -2.9)0.002Kerber 2019 [38]Favipiravir VS no treatment7290NR42.557.80.053Adjusted odds ratio0.48 (0.20–1.01)0.11
Hantavirus Pulmonary Syndrome
Chapman 1999 [39]Ribavirin VS no treatment30341 year46.750NRNRNRNRMertz 2004 [40]Ribavirin VS placebo101328 days20151NRNRNRVial 2013 [41]Methylprednisolone VS placebo303028 days27400.41Relative risk0.67 (0.32–1.39)NRWernly 2011 [42]Patients who had elective insertion of vascular sheaths and were almost concurrently intubated and placed on ECMO when they decompensated VS patients intubated when they became hypoxic and placed on ECMO when they became hemodynamically unstable.2526NR20460.048NRNRNRVial 2015 [43]Immune plasma infusion VS no treatment2919930 days14320.049Odds ratio0.35 (0.12–0.99)NR
Hemorrhagic fever with renal syndrome
Gui 1987 [44]Recombinant interferon α-2 VS placebo2525On-trial1616NSNRNRNRDu 2013 [45]RRT VS no RRTTotal (both groups): 77NANR34.3700.031NRNRNRHuggins 1991 [46]Ribavirin VS placebo126117On-trial2.48.550.01NRNRNR
Lassa fever
Ilori 2019 [47]Ribavirin VS no treatment33421During the outbreak20.771.4<0.001NRNRNRMcCormick 1986 [48]Group of AST level>150: IV ribavirin VS no therapy6360NR19550.00003NRNRNRGroup of AST level>150: Oral ribavirin VS no therapy1460NR14550.006NRNRNRGroup of AST level>150: Plasma VS no therapy2860NR50550.3NRNRNRGroup of patients with virus level superior 10^3.6 TCID50/mL: IV ribavirin VS no therapy3146NR32760.00015NRNRNRGroup of patients with virus level superior 10^3.6 TCID50/mL: Oral ribavirin VS no therapy1046NR30760.008NRNRNRGroup of patients with virus level superior 10^3.6 TCID50/mL: Plasma VS no therapy2146NR57760.12NRNRNRGroup of patients with virus level inferior 10^3.6 TCID50/mL: IV ribavirin VS no therapy32111NR9280.02NRNRNRGroup of patients with virus level inferior 10^3.6 TCID50/mL: Oral ribavirin VS no therapy29111NR7280.01NRNRNRGroup of patients with virus level inferior 10^3.6 TCID50/mL: Plasma VS no therapy32111NR16280.12NRNRNRNA, Not applicable; NR, Not reportedArgentine hemorrhagic fever (ArHF)One study on treatment was identified for ArHF: a randomized controlled trial published in 1979 assessing intravenous immune plasma obtained from convalescent donors.[11] This trial showed a significantly decrease in mortality when immune plasma is given before the ninth day of the disease (CFR = 1.1%) compared with normal plasma obtained from donors without a history of ArHF (CFR = 16.5%).Crimean-Congo hemorrhagic fever (CCHF)Nine studies on treatments were identified for CCHF: two randomized controlled trials, two non-randomized comparative studies, two case-control studies, two retrospective and/or prospective studies and one descriptive report. Most of the trials assessed oral or intravenous ribavirin, one trial assessed ribavirin +/- corticosteroids and one trial assessed immune globulins + ribavirin. Ribavirin was associated with inconsistent results across studies.Two studies reported significant results of ribavirin and ribavirin +/- corticosteroids on mortality. However, those two studies had a relatively weak design (a non-randomized comparative study [19] and a prospective and retrospective study [13]). In the randomized trial comparing ribavirin versus standard therapy alone [18], ribavirin was associated with no positive effect on mortality (CFR = 6.3% versus 5.6%). The other randomized trial was a small study (40 patients, [20]) assessing polyvalent immune globulins + ribavirin which showed with no positive effect of the treatment on mortality compared with ribavirin alone (CFR = 25% versus 11%). Therefore, no strong proof of effectiveness of specific treatment against CCHF was identified.Ebola virus disease (EVD)Seventeen studies on treatments were identified for EVD: two randomized controlled trials, two non-randomized comparative studies, four single-arm trials, eight retrospective studies and one descriptive report. Among these studies, four reported positive results on mortality. The two first studies showed that early vitamin A supplementation or IFN-beta 1a therapy may be associated with reduced mortality compared with no vitamin A supplementation or historical control (Relative risk reduction of mortality with vitamin A supplementation within 48h = 0.77 [0.59 to 0.99]; 21-day survival based on Kaplan Meier for IFN-beta 1a therapy versus historical control: 67% versus 19%). However, those results are to be taken with caution based on the weak design of the studies (retrospective study [22,23] and single-arm trial [33]).The third study was a retrospective study assessing favipiravir [25] and reported that the treatment was associated with prolonged survival compared with standard therapy alone (CFR = 44% versus 65%). However, this result was challenged by another retrospective study (adjusted odds ratio = 0.48 [0.20 to 1.01]) [38] and a single-arm trial (CFR = 54% versus 55%), [26] which reported no significant results of favipiravir on mortality.The last positive study was a randomized controlled trial assessing three treatments, the antiviral remdesivir, and the antibody-based therapies Mab114 and REGN-EB3 against ZMapp. [37] The study showed that both MAb114 and REGN-EB3 were superior to ZMapp (difference between MAb114 and ZMapp = -14.6% [-27.2 to -1.7]; difference between REGN-EB3 and ZMapp = -17.8% [-28.9 to -2.9]; in reducing mortality from EVD (with stringent findings among patients presenting with high levels of viral load).Hantavirus pulmonary syndrome (HPS)Five studies on treatments were identified for HPS: two randomized controlled trials, two non-randomized comparative studies, and one retrospective study. Only two studies reported weakly significant results. The first study was a retrospective study evaluating the impact on survival of extracorporeal membrane oxygenation (ECMO) support in patients with HPS refractory to medical treatment and the associated complications. [42] This study reported a lower mortality in patients who had elective insertion of vascular sheaths and were almost concurrently intubated and placed on ECMO when they decompensated (CFR = 20%) compared with patients intubated when they became hypoxic and placed on ECMO when they became hemodynamically unstable (CFR = 46%). The second study was a non-randomized comparative study, which compared immune plasma infusion versus no treatment. [43] The study reported a weakly significant decrease in mortality associated with immune plasma infusion (Odds ratio = 0.35 [0.12 to 0.99]).Therefore, no strong proof of effectiveness of treatment against HPS was identified.Hemorrhagic fever with renal syndrome (HFRS)Three studies on treatments were identified for HFRS: two randomized controlled trials and one retrospective study. Only two studies reported positive results. The first study was a retrospective study comparing Renal Replacement Therapy (RRT) versus no RRT [45] and showed that RRT is associated with a decrease in mortality (CFR = 34% versus 70%). However, those results are to be taken with caution based on the weak design of the study. The second study was a randomized controlled trial assessing ribavirin [46] and showed a significant reduction in mortality among patients treated with ribavirin (CFR = 2% versus 9%).Lassa fever (LF)Two studies on treatments were identified for LF: a randomized controlled trial and a descriptive report. The first study published in 1986 was a randomized controlled trial and evaluated ribavirin and convalescent plasma compared with no therapy in several subgroups [48]. The study showed that ribavirin was associated with a significantly lower mortality than no therapy (CFR = 21% versus 71%). Moreover, the second study which was a descriptive report published in 2019, [47] also reported that ribavirin was associated with a decrease in mortality.DiscussionTo our knowledge, this is the first comprehensive systematic review to summarize all published information available on worldwide cases numbers, mortality and treatments of a range of VHFs, excluding severe dengue and yellow fever.Only a few number VHF systematic reviews were previously published and focused on single VHF, mainly EVD, CCHF and LF. Some meta-analyses were also conducted but often associated with heterogeneity issues. A previous meta-analysis on EVD found a pooled CFR of 60% in Africa [49]. However, this result was associated with a very high level of heterogeneity. This is consistent with our findings, which showed that CFR varied greatly across countries in outbreaks since 2010 ranging from 28% (2014–2016 outbreak in Sierra Leone) to 75% (2014 in Mali). In terms of specific treatments, a recent systematic review [50] focused mainly on the randomized controlled trial assessing remdesivir, Mab114 and REGN-EB3 against ZMapp. [37] The authors concluded as well that both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD with differences depending on the viral load at baseline.Regarding CCHF, we identified in our review no strong proof of effectiveness of treatment. A previous meta-analysis on the efficacy of ribavirin in CCHF patients showed that ribavirin decreased the mortality rate compared with patients not treated with ribavirin.[51] However, this meta-analysis included an important number of low-quality studies such as case series. Therefore, the results should be considered with caution. Regarding Lassa fever, a previous meta-analysis on the efficacy of ribavirin showed that ribavirin was associated with lower risk of death than patients not treated with ribavirin.[52] However, heterogeneity was identified across studies and the results are mainly based on retrospective studies.Our systematic reviews also has some limitations. One limitation of our review on the number of cases and CFR identified is that our findings are based on numbers registered on the WHO and CDC websites or published numbers, which can underestimate the reality. We also decided, when available, to prioritize laboratory confirmed cases numbers. Moreover, we restricted our review of the grey literature to national health websites and references reported on the WHO and CDC websites; data on clinical trials registries (e.g. ClinicalTrials.gov) were not included here. It is also important to mention that we did not stratify our results according to species or the strain of the virus. For example, in the case of Ebola disease investigational therapeutic options, the trials of importance were conducted during the 2014–2016 western Africa outbreak and the 2018–2020 North-Kivu (Democratic Republic of the Congo) outbreak that were related to Ebola virus (species Zaire Ebolavirus) and Makona and Kikwit specific strain respectively.[36,37] With respect to treatment of other ebolavirus diseases (e.g. Soudan and Bundibugyo virus diseases), options are even more limited. Notably, the three monoclonal antibody treatments tested in the PALM trial [37], ZMapp, REGN-EB3, and MAb114, have a narrow spectrum and are ineffective against other filovirus infections. In the case of other VHFs such as HPS or LF, the sparse comparative trials assessed mainly a nucleoside inhibitor (i.e., ribavirin). No strong proof of effectiveness of ribavirin was identified for HPS. Regarding LF, the efficacy of ribavirin was not considered as specific to Lassa virus lineage. Besides, considerable uncertainty was recently even more raised about its activity as an anti-infectious agent in the management of the condition.[52–54] Another limitation of our review is that we focused our results on the mortality of the VHF. However, the mortality does not account for transmissibility of the virus, contagiousness and immune escape. Mortality rates varied also greatly across countries, especially in Africa, which can be explained by the fact that treatment facilities in some places in Africa may be limited. The study context also has an impact on the results of our review. Some authors report the challenge they can face of studying a relatively rare disease that affect widely dispersed rural areas.[41] Regarding VHFs such as EVD, authors reported difficulties during the course of their study, with for example interruption of participating centers due to violence from local community or paramilitary groups who can be suspicious of the activities in those facilities.[37] Moreover, a large number of included studies on treatment evaluation in our review were associated with a high risk of bias. This highlights the need to conduct clinical trials with a methodologically strong design.This is of most importance to adapt the methodology of clinical trials in the specific context of VHFs. A recent study explored the application of Bayesian Decision Analysis (BDA) in order to incorporate the burden of disease and disease context into clinical trials, especially for the deadliest diseases in the US, such as cancers or liver cirrhosis. [55,56] This framework allows taking into account the disease context when determining the sample size and critical value of a fixed-sample test. Therefore, an interesting next step of our review would be to use these results to conduct a BDA to evaluate the optimal sample sizes and type I errors for future VHF clinical trials.ConclusionWe observed that number of cases and mortality varied greatly across VHFs as well as across countries within each VHF. The number of studies on VHFs treatments was very limited with very few randomized trials and no strong proof of effectiveness of treatment against most of the VHFs. Therefore, there is a high need of methodologically strong clinical trials conducted in the context of VHF.Supporting informationS1 FigMEDLINE Search strategy.(DOCX)Click here for additional data file.S1 TableReferences details of each included publication.(DOCX)Click here for additional data file.S2 TableReferences details of each included WHO or CDC report.(DOCX)Click here for additional data file.S3 TableQuality Assessment of studies reporting results on treatments–Randomized Trials.(DOCX)Click here for additional data file.S4 TableQuality Assessment of studies reporting results on treatments–Non-Randomized Trials.(DOCX)Click here for additional data file.S5 TableQuality Assessment of studies reporting number of cases and/or case fatality rates.(DOCX)Click here for additional data file.S6 TableNumber of cases and CFRs of Crimean-Congo hemorrhagic fever by country (alphabetical order) and period.(DOCX)Click here for additional data file.S7 TableNumber of cases and CFRs of Ebola Virus Disease by country and period.(DOCX)Click here for additional data file.S8 TableNumber of cases and CFRs of Hantavirus Pulmonary Syndrome by country and period.(DOCX)Click here for additional data file.S9 TableNumber of cases and CFRs of Hemorrhagic fever with renal syndrome by country and period.(DOCX)Click here for additional data file.S10 TableNumber of cases and CFRs of Lassa fever by country and period.(DOCX)Click here for additional data file.S11 TableNumber of cases and CFRs of Marburg virus disease by country and period.(DOCX)Click here for additional data file.S12 TableNumber of cases and CFRs of Rift Valley fever by country and period.(DOCX)Click here for additional data file.S13 TableNumber of cases and CFRs of Alkhurma hemorrhagic fever, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, Chapare hemorrhagic fever, Lujo hemorrhagic fever, Omsk hemorrhagic fever, Sabia hemorrhagic fever and Venezuelan hemorrhagic fever by country and period.(DOCX)Click here for additional data file.S14 TableDescription of the treatment and comparator groups of each included studies reporting results on VHF treatments.(DOCX)Click here for additional data file.
Medicine and Health Sciences Pharmacology Routes of Administration Intravenous Injections Medicine and health sciences Medical conditions Tropical diseases Neglected tropical diseases Viral hemorrhagic fevers Crimean-Congo hemorrhagic fever Infectious diseases Viral diseases Medical Conditions Infectious Diseases Viral Diseases Hemorrhagic Fever with Renal Syndrome Tropical Diseases Neglected Tropical Diseases Viral Hemorrhagic Fevers Ebola Hemorrhagic Fever Marburg Hemorrhagic Fever Argentine Hemorrhagic Fever Research and Analysis Methods Research Design Retrospective Studies